Effect of Doxorubicin on Cardiac Myocytes: Role of Apoptosis, Autophagy and other Proteolytic Pathways by Mistiaen, Wilhelm P
 International Journal of Cardiology and Lipidology Research, 2016, 3, 31-43 31 
 
 E-ISSN: 2410-2822/16  © 2016 Cosmos Scholars Publishing House 
Effect of Doxorubicin on Cardiac Myocytes: Role of Apoptosis, 
Autophagy and other Proteolytic Pathways 
Wilhelm P Mistiaen1,2,* 
1University of Antwerp, Faculty of Medicine and Health Sciences, Universiteitsplein 1, 2020 Antwerp, Belgium 
2Artesis-Plantijn University College Antwerp, Noorderplaats 2, 2000 Antwerp, Belgium  
Abstract: Doxorubicin is a very effective chemotherapeutic agent. However, its use is limited by serious cardiac side 
effects, including long-term irreversible cardiac failure which is often fatal. These effects are related to the cumulative 
dose but other factors also play a role. Through a systematic search in an electronic database, manuscripts dealing with 
this matter were included. Exposure of the heart to doxorubicin s result in three types of stress: 1] genotoxic, 2] energetic 
and 3] oxidative stress. These effects are closely related with the dependence of the heart on oxidative phosphorylation, 
its low defenses against reactive oxygen species and with the peculiarities of mitochondria, which are abundantly 
present in cardiac tissue. In most manuscripts, the cellular effects of doxorubicin are documented by changes in 
enzymatic pathways within cardiomyocytes. These pathways have mutual influences, which complicate the interpretation 
of results. These pathways often result in proteolysis, cellular damage and apoptotic cell death. Necrosis and autophagy 
are also involved as mechanisms. Most of the included manuscripts deal with in-vitro experiments with anti-oxidant 
agents, using cardiomyoblasts and H9c2 cell lines as well as in-vivo short-term murine models. However, long-term 
animal models are lacking. Clinical articles and experiments with cells other than cardiomyocytes are few. The effects of 
doxorubicin on the extracellular matrix also needs further exploration. These areas need further exploration. 
Keywords: Doxorubicin, Reactive oxygen species, Genotoxic stress, Energetic stress, Apoptosis, autophagy, 
Mitochondria. 
INTRODUCTION 
Doxorubicin has been introduced from 1960’s [1] as 
an effective treatment against several types of cancer. 
These “cell-cycle non-specific agents” are derived from 
Streptomyces bacteria [2] and are very effective. Its 
use, however, is limited by their short and long-term 
cardio-toxic effect which ranges from asymptomatic 
cardiac changes such as lower left ventricular [LV] 
mass, diastolic and systolic dysfunction, abnormal 
regional wall contractility to cardiomyopathy, overt 
heart failure and even cardiogenic shock [3-7]. There is 
an acute, an early onset and a late onset doxorubicin 
toxicity [1, 8]. The acute toxicity manifests itself as 
hypotension, tachycardia and arrhythmias [9]. It 
appears immediately after treatment and disappears 
after the discontinuation of the treatment. In 1973, a 
high lethality of CHF was observed. This was refractory 
to every treatment available at that time. A maximal 
dose of 550 mg/m² was proposed to avoid such 
calamities. This event could be reversible [1]. The 
early-onset cardiotoxicity can appear in the first year 
after treatment with doxorubicin; it presents itself as 
chronic dilated CMP. The late-onset cardiotoxicity 
develops after a period of seemingly normal LVF, with 
a latency period which can last several years. 
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Echocardiographic abnormalities have been found in 
65% of the patients [1]. LV dysfunction evolves to an 
irreversible CHF, with arrhythmias and fibrosis. This is 
clinically most relevant [9]. Cumulative dose, irradiation 
and length of follow-up had a significant effect [10]. 
These events can are dose dependent, cumulative and 
irreversible [11]. Its mechanisms are poorly 
understood. In an old retrospective series, prevalence 
of clinical heart failure was 2%with a mortality of 71% 
[12]. LV dysfunction at 10 years was detected in 18% in 
patients who received less than 500 mg/m² 
doxorubicin; this was 63% in patients who received 
more than 500 mg/m² [10]. High age and prior 
cardiovascular morbidity will increase these events. 
Nowadays, the medical treatment and the follow-up 
has improved considerably. One-third of the patients, 
however, do not recover from a reduction of LVEF after 
treatment with doxorubicin [13]. The reason for this 
irreversibility in long-term cardiac dysfunction is cell 
death, either by apoptosis or by necrosis [1]. These 
events are responsible for the increase in need for 
heart transplantation as definitive treatment for end-
stage heart failure in long-term cancer survivors [14]. 
The risk for adverse cardiac events increases with 
the cumulative dose [15], starting from histopathologic 
changes at 240-250mg/m² [1], and a sharp increase of 
CHF from 550mg/m² [1], with 3 times increase in 
cardiac mortality after 20 to 30 years [16]. Remarkably, 
some patients who received more than 1000 mg/m², 
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however, did not develop CMP [15]. This indicates that 
unknown factors are involved, which could include 
differences in metabolism or differences in sensitivity to 
ROS. It is also possible that events in other cells than 
cardiomyocytes, present within the heart need to be 
investigated [16]. Moreover, age below 4 years or over 
65 years, hypertension, coronary artery disease, prior 
mediastinal irradiation, concomitant treatment with 
trastuzumab or paclitaxel and genetic predisposition 
increases the risk for cardiotoxicity [1, 17]. The early 
recognized actions of doxorubicin s are attributed to 
inhibition of synthesis of DNA and RNA by intercalation 
of base pair, inhibition of topo-isomerase II enzyme 
preventing transcription and replication of genetic 
information [18] and inhibition of the ligase enzyme to 
repair DNA, resulting in fragmentation of DNA [19]. A 
more recently postulated mechanism is eviction of 
histones [20]. The aim of this review is to describe the 
more recently observed cardiac specific events after 
administration of doxorubicin.  
METHODS 
Search through Web of Science, from 2011 to 2016 
resulted for the search terms (autophagy AND 
anthracyclines AND heart) in 5 articles. The search 
terms (programmed cell death AND anthracyclines 
AND heart / cardiac / myocard*) led to one additional 
article while (apoptosis AND anthracyclines AND heart) 
resulted in 42 manuscripts. Secondary literature was 
included if historically relevant. The search was 
focused on the effect on cardiomyocytes in vitro as well 
as in vivo studies, not on arrhythmias, ischemia or 
pericarditis. In vivo as well as in vitro studies were 
included.  
RESULTS 
Peculiarities of the heart, of mitochondria and of 
mitochondrial DNA (Table 1) are of major importance in 
understanding the effects of doxorubicin. The included 
studies showed that administration of doxorubicin 
results in a dose dependent reduction of the weight of 
the heart, with edema, disorganization of myofibrils, 
formation of vacuoles, lymphocytic infiltration and 
increase of fibroblasts and collagen, as well as LV [left 
ventricle] failure, with reduction of LVEF and of 
fractional shortening [21]. There is an effect on the 
cytoskeletal apparatus: 1) an impaired actin-myosin 
interaction [22] 2) a disruption of the formation of 
desmin which acts as a regulator of sarcomeres [23] 
resulting in a disorganization of these sarcomeres [24], 
and 3) a reduction of dystrophin, resulting in an 
increased permeability of the sarcolemma [21]. From 
these studies, it becomes also evident that 
mitochondria are a main target of doxorubicin. Since 
mitochondria make up to 45% of the volume in 
myocardial tissues [6, 7], the heart is very vulnerable to 
doxorubicin. Moreover, doxorubicin concentration in 
mitochondria is 100 times higher compared to plasma 
[25, 26]. Many of these effects can be related to 
Reactive Oxygen Species or ROS, such as hydrogen 
peroxide, hydroxyl radicals and superoxide. 
Mitochondria are the main generators but also the 
targets of ROS. These organelles are involved in the 
signaling and buffering of calcium of the cytosol which 
has an importance of apoptosis. Apoptosis can be the 
result of mitochondrial damage [6]. Mitochondria have 
some peculiarities. Cardiolipin is a complex four-tail 
lipid structure which constitutes 20-45% of the inner 
mitochondrial membrane. It serves as a proton trap and 
as cofactor for the mitochondrial respiratory enzymes. 
It plays a role in the coupling of the respiratory chain 
and phosphorylation [6, 7, 9].  
Table 1: Peculiarities of the Heart and of Mitochondria 
The Heart 
• High volume % of mitochondria [45%] with heavy reliance on 
oxidative phosphorylation 
• Low in catalase and dismutase 
• Small pools of ATP, which can be replenished by 
phosphocreatine  
Mitochondria 
• High amount of cardiolipine in the inner membrane with high 
affinity for doxorubicin  
• Mitochondrial DNA without histone 
• Close proximity of mitochondrial DNA to respiratory enzymes 
• Lack of reparative systems for mitochondrial DNA 
• No histones in mitochondrial DNA with possibility to 
accumulate oxidative damage in comparison to nuclear DNA  
• Variable copies of mitochondrial DNA, depending on the cell 
type and developmental stage  
 
Mechanisms and Reasons for Mitochondrial 
Cardiotoxicity of Doxorubicin 
The classic mechanisms of doxorubicin have been 
explored for some time. There are several levels 
through which doxorubicin, given at clinical relevant 
dose,acts [16, 27]. These include 1) energy stress, 2) 
oxidative stress and 3] genotoxic stress. It should be 
noted that these levels show mutual interaction which 
complicates their representation. Moreover, some other 
organelles are involved. These types of stress result in 
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loss of cellular components and in cell death. The more 
important are ubiquitin proteasome proteolysis, 
apoptosis, autophagy, and some intermediary modes 
of cellular demise. These are summarized in Table 2.  
Table 2: Enzymes and Pathways Involved in Different 
Types of Stress 
Energy Stress 
• Peroxisome proliferator-activated receptor-alpha [PPAR] 
• Peroxisome proliferator-activated receptor receptor-gamma 
• AMP-activated protein kinase [AMPK] 
• Damaging creatine kinase  
• Failure of the respiratory chain  
Oxidative Stress 
• NADPH oxidase [with Rac1 component as essential part] 
• NADH dehydrogenase  
• Histone HA2X deacetylase  
• Cytochrome c reductase  
• Acetylation of p53  
• Endothelial nitric oxide synthase  
• Extraction of iron from ferritin with subsequent complexation  
• Inactivation of glutathione peroxidase 
• Decrease of Cu-Zn superoxide dismutase  
• Clearance of catalase by increased autophagy 
• MDR1 or multi drug resistance protein-1 as efflux pump  
Genotoxic Stress  
• Inhibition of topo-isomerase II 
• Inhibition of RNA polymerase  
• Activation of Akt / Protein kinase B with T-cell lymphoma 1A 
as cofactor  
• Inhibition of AMPK – related to ATP/AMP ratio  
• Activation of Mitogen-activated protein kinase [MAPK] 
Other Organelles, with Increase in the Calcium Load of the 
Cytosol 
• Interaction with ryanodine receptors of the endoplasmatic 
• Activation of the non-lysosomial protease calpain 
• Stimulation of Ca/calmodulin protein kinase 
Apoptosis  
• Upregulation of the extracellular signal-regulated kinase 
[ERK1/2] pathway  
• Activation of the pro-apoptotic c-Jun N-terminal kinase [JNK] 
pathway 
• Inactivation of phosphatidyl-inositl-3-kinase [PI3/Akt or protein 
kinase B] pathway 
• Inactivation of neuregulin 
• Downregulation of GATA4, which is responsible for the 
embryonic cardiac development  




An increase in AMP/ATP ratio indicates a loss of 
ATP and is observed in an in vitro model [6, 27]. In 
case of high energy demand, the small pool of ATP in 
cardiomyocytes can be replenished by phospho- 
creatine. Creatine kinase act as modulator of the 
energy reservoir but this can be damaged by ROS, 
thereby disrupting energy homeostasis [7, 28]. As 
adaptation to decreased ATP output in doxorubicin-
toxicity, cardiomyocytes switch over from fatty acid to 
glucose as substrate [7, 29, 30]. However, 
phosphofructokinase and the expression of peroxisome 
proliferator-activate receptor (PPAR)-gamma are also 
affected by doxorubicin. This impairs the uptake of 
glucose and makes matters worse [31]. The heart is 
less resistant to additional energy challenges in 
presence of growth stimulating signals. As compensa- 
tion for the inability of AMP-activated protein kinase 
(AMPK) to fulfill its role in energy homeostasis, the 
creatine kinase energy buffer and transfer system has 
been upregulated in the acute and subacute setting 
[27]. In an combined in-vivo and in-vitro murine model, 
the effect of doxorubicin on the pathways of PPAR 
alpha-PGC-1alpha co-activator were investigated using 
PPAR inhibitors and activators. PCG-1alpha plays a 
role in the biogenesis of mitochondria making muscles 
more dependent on oxidative metabolism and less on 
glycolysis. In the doxorubicin group, PPAR/PGC was 
lower, with mitochondrial dysfunction and low ATP, and 
reduced mitochondrial membrane potential. Glucose 
and free fatty acid consumption had increased. More 
ROS was present, as was also apoptosis. The 
PPAR/PGC-1alpha pathways are involved in energy 
metabolism and in apoptosis in cardiomyocytes [32]. 
The cardiac function can acutely be impaired by the 
energy stress [7, 28].  
Oxidative Stress 
Doxorubicin has a high affinity to cardiolipin, which 
is located within the inner mitochondrial membrane, 
and binds irreversibly to it [1, 6, 7, 33, 34]. It places 
doxorubicin close to the electron-transport chain, 
permitting formation of ROS, causing damage 
throughout the cytosol, the mitochondria and other 
subcellular components [35]. Protein oxidation is 
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mainly expressed as carbonyl formation in the 
subacute model at 6 weeks [27]. ROS persists for 5 
weeks after discontinuation of doxorubicin [16]. The 
Rac1 component of NADPH oxidase plays an 
important damaging [16] role in the formation of ROS: 
its inhibition mitigated ROS production and hence 
apoptosis, while over expression of Rac1 worsened 
apoptosis. Inhibition of Rac1 preserves the histone 
HA2X deacetylase activity and prevents activation of 
p53. Scavenging ROS did not change the histone 
deacetylase H2AX activity, neither was activation of 
p53 altered. This indicates that Rac1 mediated 
cardiotoxicity involves both ROS dependent and 
independent pathways [36]. ROS can damage creatine 
kinase and contribute to the energy stress. Increase in 
production of ROS [6, 37] by doxorubicin occurs by 
utilizing NADH dehydrogenase / cytochrome c 
reductase and endothelial nitric oxide synthase [38] 
and by complexing iron, which is extracted from ferritin 
[21, 39-43]. Additionally, doxorubicin releases iron from 
its stores [9] and complexes this metal. This catalyzes 
hydrogen peroxide into hydroxyl radicals, adding to 
oxidative stress [1]. The reduction of doxorubicin, by 
adding one electron to the quinone moiety of the C-ring 
leads to formation of semiquinone which can react with 
molecular oxygen. By formation of superoxide, radicals 
can be formed by redox cycling, whereby the quinone 
structure has regenerated [1, 44]. This leads to the 
formation of ROS [45] but also to the abolishment of 
anti-oxidant defenses such as inactivation of GSH-1 
peroxidase with a decrease of Cu-Zn superoxide 
dismutase [7, 40, 41]. Over expression of manganese 
superoxide dismutase alleviates apoptosis [1]. One 
molecule of doxorubicin leads to many molecules of 
free radicals through redox cycling! The respiratory 
chain starts to fail which contributes to the energy 
stress [46]. This generation of ROS causes peroxida- 
tion of lipids, inflammation and apoptosis [9], which is 
clinically relevant [16]. The clinical relevance of 
oxidative stress was documented in women with breast 
cancer: those who experienced a lowering of LVEF 
also had elevated levels of plasma byproducts of ROS 
[17]. The only other clinical article investigated the 
effect of BRCA 1 and 2 gene mutations on the effects 
of doxorubicin on the heart in breast cancer patients. 
Except for higher oophorectomy and early menopause, 
groups with and without those mutations and without 
mutations were comparable [47].  
Genotoxic Stress 
Doxorubicin enters the cells through passive 
diffusion and bind to proteasomes [9, 48]. This complex 
is translocated to the nucleus, especially in dividing 
cells. Doxorubicin dissociates from the proteasomes 
and binds to DNA by intercalation. This has a DNA 
adenine methyltransferase effect and results in 
inhibition of protein synthesis and alteration of many 
transcriptional factors. Nuclear proteins are displaced 
and chromatin aggregates. Topoisomerase II and RNA 
polymerase are inhibited [9]. Lesions in nuclear and 
mitochondrial DNA are found during the acute in-vitro 
experiments, resulting in apoptosis. DNA-dependent 
protein kinase is a crucial component in the DNA repair 
machinery. It signals to Akt/PKB (protein kinase B) 
which promotes survival after genotoxic stress. At the 
same time AMPK is inhibited [27]. As a response to 
DNA damage, p53 is activated by acetylation and the 
histone H2AX is phosphorylated [36]. An example of 
interrelation between genotoxic, energetic and 
oxidative stress has been observed in the effect of 
doxorubicin on AMPK or AMP activated protein kinase 
[27,36]. AMPK is activated by stress such as lowering 
of ATP and hence ADP/ATP ratio. ATP generating 
processes are activated by AMPK in order to restore 
the energy supply. Doxorubicin can induce “energy 
stress” in this respect because AMPK is paradoxically 
suppressed and hence the shortage of ATP remains. 
There was no evidence for an altered “upstream 
signaling” by doxorubicin which could account for this 
effect. Another mechanism by which AMPK is 
downregulated by doxorubicin might be the cross talk 
of AMPK with Akt/PKB (protein kinase B) and with 
MAPK (Mitogen-activated protein kinase). The 
activation of Akt pathway is a consequence of 
genotoxicity, while stimulation of MAPK/ERK is due to 
an increase in ROS [1, 27]. This contains some 
cytoprotective elements and could counteract 
apoptosis caused by genotoxicity [27]. Remarkably, 
defects in DNA repairing enzymes such as 
polymerases seem to protect against doxorubicin 
toxicity. On the other hand, defects in BCRA2 gene 
exaggerates apoptosis and CHF. Cellular DNA 
reparative mechanisms are of paramount importance 
but defects in some reparative pathways results in 
enhanced sensitivity to doxorubicin while other defects 
have a protective effect [9]. 
Effect on other Organelles than Mitochondria  
Doxorubicin also interferes with ryanodine receptors 
/ ion channels of the sarcoplasmatic reticulum which 
are responsible for the release of calcium ions during 
the excitation-contraction coupling and the buffering of 
cytosolic calcium [49]. Hence, the calcium homeostasis 
is disturbed. The cytosolic calcium content increases. 
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The protein folding capacity of the endoplasmatic 
reticulum alters because the combination of increased 
ROS and disturbed calcium homeostasis. The 
accumulation of oxidative damaged and misfolded 
proteins leads to endoplasmatic reticulum stress. 
Moreover, the removal of such proteins by the ubiquitin 
proteasome pathway could also be disturbed. Toxic 
aggregates contributes to myocardial dysfunction and 
worsens the effect of ROS [33]. Another effect of the 
increased load of intracellular calcium is the activation 
of the non-lysosomial protease calpain which might be 
responsible for the damage to the myofibrillar proteins, 
including dystrophin [21]. Doxorubicin also stimulate 
Ca/calmodulin protein kinase, which results in an 
increased leak of calcium from the sarcoplasmatic 
reticulum [16], with an impact on contraction and 
relaxation of cardiomyocytes [9].  
Modes of Loss of Cellular Components and of Cell 
Death  
Doxorubicin modulates p53 activity [9], which 
causes a series of events, including a decrease in 
membrane potential [6]. The mitochondrial transition 
pore opens [6, 7] with release of cytochrome C [1, 50] 
as trigger for apoptosis [25, 27, 51]. Apoptosis, of 
which the major steps are shown in Table 3, is also 
enhanced by the upregulation of the extracellular 
signal-regulated kinase (ERK1/2) pathway [52, 53]. 
Activation of the pro-apoptotic c-Jun N-terminal kinase 
(JNK) pathway with inactivation of the anti-apoptotic 
phosphatidyl-inositol-3-kinase (PI3/Akt or protein 
kinase B) pathway by daunorubicin has been observed 
in an in-vitro rodent model. However, JNK and Akt 
pathways show “cross-talk” which can complicate their 
actions. Anyway, activation of PI3/Akt pathway could 
make cells resistant to chemotherapy, while down 
regulation of Akt could make tumor cells more 
sensitive. BcL-2 and BcL-xL are initially upregulated 
after exposure to doxorubicin, but this followed by a 
decrease. However, treatment with anti-oxidants 
improves the LV function through increase in Akt, Bcl-2 
and decrease of caspase activity [1]. Neuregulin, which 
is a pro-survival factor, plays a role herein and protects 
against apoptosis [1, 16]. For cardiac stem cell survival, 
a combination of chemotherapeutic agents may be 
promising [54]. However, in an acute setting – a 
perfused isolated heart [27], ERK as survival promoting 
kinase was activated and apoptosis was low, while in 
the subacute model in living animals with 4 weeks after 
last injection, the pro-apoptotic JNK was activated. 
Cardiomyocytes are relatively resistant to apoptosis, 
but when it occurs, it contributes heavily to heart 
failure. Upregulation of Akt/PKB preserves viability of 
the cells and is cardioprotective in doxorubicin 
treatment [27]. Doxorubicin trigger poly (ADP-
ribosyl)ation of p53, which in turn serves as a 
mechanism for p53 nuclear accumulation. Consistently, 
daunorubicin promotes increased nuclear expression of 
p53, without changing total cellular p53 expression. 
This doxorubicin -induced nuclear presence of p53 is 
regulated through redox-dependent mechanisms. The 
down regulation of GATA4 factor, which is a 
cardiomyocyte survival factor regulating many cardiac 
genes including the embryonic cardiac development, 
plays a role herein [16, 36, 55]. If anti-oxidant defenses 
are overwhelmed, the mitochondrial inner membrane 
permeability transitional pore opening allows an influx 
of cytosolic solutes, causing a mitochondrial swelling, 
degeneration and cardiomyocyte necrosis [9]. 
Table 3: intrinsic Pathway of Apoptosis, Involving 
Mitochondria 
Through Damage of DNA and ROS 
• Activation of p53 if DNA damage is irreparable  
• Dimerization of Bak and Bax proteins (inhibited by BcL) 
• Opening of the mitochondrial permeability transition pore 
• Depolarization of the mitochondrial membrane potential 
• Release of cytochrome c and loss of oxidative 
phosphorylation  
• Formation of Apaf1 (apoptotic protease activating factor 1)  
• Activation of caspase 9 
• Activation of caspase 3 
• Condensation of chromatin, nuclear fragmentation, membrane 
bleb formation and rearrangement of the cytoskeleton 
• Apoptosis  
• Phagocytosis by polymorphonuclear cells, without 
inflammation  
 
Mitochondrial fission which is formation of small 
rounded mitochondria, as a sign of stress, has been 
associated with the production of ROS and with 
autophagy of mitochondria, also called mitophagy [56]. 
An increase in autophagy flux with an increase in 
accumulation of autophagosomes was observed was in 
cultured rat cardiomyocytes. It seems that autophagy is 
initially upregulated as compensation for cytotoxic 
stress [57] by activating Bcl-2 and the autophagy 
related genes and recruitment of light-chain-3 [46]. But 
this is followed by apoptosis and necrosis after longer 
exposure to doxorubicin. The protein degradation 
machinery is downregulated leading to an 
accumulation of poly-ubiquinated proteins and 
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autophagosomes. Aging of cardiomyocytes could 
accelerate and make them more susceptible for 
[further] exposure to doxorubicin [57]. Mitochondrial 
biogenesis is suppressed as a chronic consequence of 
exposure to doxorubicin s [58]. 
Autophagy, of which the major steps are shown in 
Table 4, acts as a double edged sword. On the one 
hand, it serves as a clearance and renewal mechanism 
and could reduce cell death, when it inhibits apoptosis. 
This has been observed in in-vitro as well as in-vivo 
murine models: production of ROS and apoptosis were 
mitigated by stimulation of autophagy and the 
morphology and function of mitochondria improved. On 
the other hand, inhibition of autophagy by bafilomycin-1 
results in mitochondrial fission and cell death [59]. On 
the other hand, autophagy could lead to cell death in 
chronic doxorubicin toxicity, by allowing or acting 
synergistically with apoptosis [59-61] with ensuing loss 
of cardiomyocytes and cardiomyopathy. This could 
depend on the cell type in use [neonatal versus adult, 
the concentration] and the duration of treatment with 
doxorubicin. Inhibition of autophagy or activating 
protein synthesis through mTOR, Akt and ERK1/2 
pathways seems to restore the expression of 
contractile proteins [62]. The interplay between 
autophagy and apoptosis is documented by the fact 
that in acute doxorubicin toxicity, p53 inhibits mTOR. 
Ablation of p53, however, is not sufficient to reduce 
cardiac dysfunction. The functional and structural 
integrity of the cardiac sarcomere requires a tight 
balance between protein synthesis and protein 
degradation by autophagy and UPP. Between both 
systems, a cross-talk exists [59]. It should be noted that 
cell death with autophagy is not the same as cell death 
by autophagy. But over-activation of autophagy can 
lead to cell death with other characteristics such as an 
increase in autolysosomes, typical nuclear changes 
and dilated endoplasmatic reticulum. A new term, 
“autosis” has been coined [63]. Moreover, other types 
of cell death such as necroptosis by doxorubicin also 
has been observed. This is caused by damage to DNA, 
increase ROS production followed by depletion of ATP 
and cell death independent from caspase. Both 
apoptosis and necrosis have been observed using 
doxorubicin [54]. Autophagy could remove catalase 
which make increased autophagy responsible for 
increase in ROS [46, 64]. Autophagy is also sensitive 
to ROS, with an increase in endogenous superoxide 
dismutase, catalase and glutathione peroxidase. These 
enzymes might have an effect on autophagy [46].  
Table 4: Pathway of Macro-Autophagy 
The Endoplasmatic Reticulum /Trans-Golgi -Endosomes 
Membrane Contribute to the Formation of a Bilayer Lipid 
Membrane Called Phagophore. This can Start through MAPK 
/ Erk1/2 Signaling  
• Conjugation of Atg5 (autophagy gene product 5) with Atg12; 
Atg7 and Atg10 play a supporting role herein  
• Interaction with Atg16 
• Polymerization at the phagophore 
• Processing of LC3 (light chain 3 protein conjugated with 
phosphatidyl ethanolamine) with insertion to the phagophore 
• Phagophore expansion 
• Engulfing target at random or selective (cytosol, organelles)  
• Sequestering in autophagosome 
• Maturation through fusion with lysosome  
• Degradation by lysosomial enzymes  
 
One of the few clinical – epidemiologic study 
investigated the difference in genome wide transcript 
between women who had a LVEF below versus above 
40%. Especially TCL1A or T-cell lymphoma 1A (a co-
activator of the Akt pro-survival factor) and an efflux 
pump of doxorubicin the MDR1 or multi drug resistance 
protein-1 were involved. Inhibition of the latter in an in-
vitro experiment worsens susceptibility of the heart to 
doxorubicin. TCL1A reduction causes increased 
sensitivity to apoptosis and leads also to a reduced 
level of MDR1 which enhances cardiac levels of 
doxorubicin s [17]. The Akt pathway as well as the role 
of MDR1 has been established in a clinical article 
where breast cancer patients were treated with 
doxorubicin s: women who experienced a reduction of 
LVEF below 40% were compared with those without 
such changes according RNA transcripts in plasma: 
those with a decreased LVEF showed also a lowering 
for MDR1 and for a co-activator of Akt transcripts [17].  
The ubiquitin proteasome pathway (UPP), of which 
the major steps are shown in Table 5, is activated by 
doxorubicin [33, 65], with an increase in 20S 
proteasomes, E3 ubiquitin ligases and hence increased 
degradation of proteins [16]. Ischemia and other 
cardiac disorders can damage this pathway, adding to 
the effects of chemotherapy [59]. The in-vivo tumor 
bearing murine as well as in-vitro rat cardiomyoblasts 
show that myofibrils become less organized after 
exposure to doxorubicin because of their targeting and 
subsequent breakdown by UPP [33]. Actin becomes 
disorganized and depolymerized. Absence of 
dystrophin increases the sensitivity of the heart to 
doxorubicin [16]. In lower dosage, UPP was 
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upregulated [33, 46, 53]. These seemingly contradic- 
tory events depend on the amount of doxorubicin 
molecules bound on the proteasome [48].  
Table 5: Pathway of the Ubiquitin Proteasome 
Proteolysis 
Tagging of the Substrate Protein by Multiple Ubiquitin 
Molecules by Covalent ATP Dependent Binding to the 
Epsilon-Amine of Lysin Residues by Ubiquitin Activating 
Enzyme E1 
• Ubiquitin conjugating enzyme E2 
• Ubiquitin ligating enzyme E3 
• E3 also binds to E2 
• Formation of E2-E3-substrate complex 
• Recognition by specificity  
• Degradation by the 26S proteasome (20S catalytic core and 
19S regulator of degradation) 
• Recycling of ubiquitin  
 
Effect of Doxorubicin on other Cells and on ECM  
The undifferentiated cardiac stem cells are 
supposed to be more vulnerable but results seem to 
suggest that in differentiated cells, upregulation of 
oxidative phosphorylation is observed, with a 
compensatory increase in super oxide dismutase. The 
higher degree of reliance of mature cells on 
mitochondrial metabolism could be related to the 
toxicity induced by doxorubicin [8]. Nevertheless, 
cardiac stem cells are a target of doxorubicin [54] and a 
therapeutic goal is their protection. Their elimination by 
doxorubicin could be held responsible for long-term 
CHF. Shortening of telomeres and premature 
expression of p16 could account for senescence. 
Abnormalities were also observed in endothelial 
progenitor cells [16]. Doxorubicin activate the NFkB 
factor in endothelial cells, which results in apoptosis. 
Decreased plasma levels of endothelin-1 can be found 
after exposure which correlates with a decreased 
cardiac function. In cancer survivors, there is an 
increase in vascular inflammation, vascular wall 
stiffness and of atheromatosis. Erythropoietin 
derivatives restore the cardiac microvasculature and 
endothelial differentiation. One needs to take into 
account that acute effects in the laboratory differs from 
the mid and long-term clinical results [16].  
There is a role of elevated TGF-beta in patients with 
heart failure; it serves to remodel the myocardium with 
fibrosis. Proliferation and migration of endothelial cells 
also reduce. Inhibition of the TGF-β pathway alleviates 
the detrimental effects of doxorubicin on endothelial 
cells in vivo. The inhibition of TGF-β pathway seems a 
valid strategy for preserving and even enhancing of 
myocardial capillary networks and prevention of 
microvascular remodeling [66]. Cardiomyocytes and 
coronary microcirculation are tethered in a network 
consisting of collagen, proteoglycans, glycoproteins 
and glycosaminoglycans. This network is maintained 
and balanced by fibroblasts. It has several functions, 
including a scaffold for myofiber alignment, prevention 
overstretching of sarcomeres, transmission and 
coordination of forces, involvement in vasomotor 
reactivity in myocardial microcirculation, controlling 
release of cytokines. When the synthesis exceeds 
degradation, fibrosis is the result. In the case of the 
opposite, this scaffold will disrupt. Doxorubicin have 
acute and chronic effect on the ECM [67]. The acute 
effects include upregulation of matrix metalloproteinase 
MMP-9 (through p38/MAPK, peroxynitrite), of MMP-2 
(through c-Jun N-terminal Kinase / NADPH oxidase, 
peroxynitrite) and of MMP-1 and MT1-MMP. ECM 
components such as fibronectin, tubulin, myosin-light 
chain kinase decrease, resulting in fibrosis and loss of 
cardiomyocytes, vacuolization. The actin cytoskeleton 
reorganizes with shrinkage and detachment of the cells 
by affecting the interface between these cells and the 
ECM. Through the loss of extracellular superoxide 
dismutase, endothelial cells become damaged 
fibroblast proliferate [68]. The chronic effects are 
consequences of intracellular changes of activity of 
NADPH oxidase and of nitric oxide synthase 2 which 
leads to apoptosis and fibrosis. The increase in MMP-2 
persists and tissue inhibitor of MMP (TIMP-3) has 
reduced. The ECM preserving thrombospondin-2is 
absent. This is associated to impaired Akt signaling 
pathway [there is a feedback loop between 
thrombospondin and Akt]. Cathepsins and cystatins are 
in close balance in healthy tissues. An increase of 
Cystatin C correlates with inhibition of cathepsin B and 
is followed by an accumulation of collagen. Chemotaxis 
of inflammatory cells results in a wound healing 
response: necrotic cells and collagen debris are 
removed. This degradative phase ends after one week, 
when TIMP are upregulated. Inflammatory cells and 
myofibroblasts generate TGF-beta1 which deposits 
collagen and inhibits matrix degeneration. This results 
in interstitial fibrosis, scarring and extensive cardiac 
ECM remodeling [69].  
There is one interesting acute animal study with 
pregnant rats. Study of fetal and maternal cardiac 
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tissue showed after administration of a high dose 
doxorubicin unaltered fetal hearts while in maternal 
hearts there was obvious loss of weight, moderately 
reduction of LVF, with apoptosis and a decreased DNA 
turnover. The fetal plasma concentration of doxorubicin 
reached about 6% of that in the maternal circulation. 
Plasma BNP was lowered by doxorubicin, while in fetal 
circulation, BNP was higher – which could be 
considered as counter-regulatory and protective. It 
seems that fetal hearts are protected. Fetal growth 
restriction has been observed in clinical conditions, but 
this could be explained by indirect mechanisms such 
as maternal malnutrition and placental dysfunction [70]. 
These data might be useful for young women who 
develop a malignancy during pregnancy. 
Testosterone had a protective effect against 
doxorubicin in rat cardiomyoblasts by counteracting 
senescence, which might be important for gender 
differences in cardiotoxicity of cancer treatment in 
young patients. The mechanisms involved were the 
androgen receptor, phosphatityl-inositol-3 kinase, p53, 
phosphorylation of Akt and phosphorylation of nitric 
oxide synthase 3 [71]. These results were not 
confirmed by an in vivo adult rat model studying the 
effect of gender on doxorubicin toxicity: signs of 
cardiomyopathy and mortality were higher in male rats 
compared to female animals. Although oxidation levels 
nor the apoptosis signaling pathways were altered by 
doxorubicin, the level of total AMPK was decreased in 
male rats, together with the markers of mitochondrial 
biogenesis and cardiolipin content [72]. 
Cardio-Protective Measures  
Several attempts to reduce the cardiotoxicity of 
doxorubicin s have been developed. Only few of them 
proved to be clinically significant. Dexrazoxane has 
been used as chelator of iron [1, 4, 16, 73, 74]. 
Liposomal and hyaluronic acid preparations of 
doxorubicin s lower the delivery of the agent to the 
heart [1, 9, 42]. PEGylated liposomal doxorubicin 
showed a reduced cardiotoxic effect with less ROS and 
apoptosis and improved cardiac function [16, 75]. 
Endurance exercise also has a protective effect by 
inhibiting autophagy. Mitochondrial adaptations could 
make cells more resilient to ROS, proteolysis and 
apoptosis [27, 37]. 
Cardio-protective agents such as antioxidants, 
scavengers of radicals, with anti-apoptotic or anti-
inflammatory properties are less convincing and 
probably clinically less effective. These agents include 
co-enzyme Q, vitamins C and E, riboflavin, the 
flavonoid quercetin [76], carvacrol [34], tanshinone 2A 
[11, 77], arjunolic acid [78], and nutrients such as 
carnitine, thiamine, vitamin D, folic acid and omega-3 
fatty acids [6, 38]. Melatonin has also been investigated 
thoroughly [7]. Vitamin E is clinically ineffective as anti-
oxidant [1]. Some substances such as safranal with 
corcins activated mTOR, thereby inhibiting autophagy 
but also apoptosis with consequently preserving 
contractile proteins [79]. Some substances such as 
carnitine improved also the anti-apoptotic status, the 
generation of prostacyclin, promoting Akt phosphoryla- 
tion and signaling [11], catalase and superoxide 
dismutase through PPAR alpha [38]. Docosahexaenoic 
acid, combined with epirubicin, on the other hand 
resulted in more oxidized lipids in tumor cells, but not in 
healthy tissues [80]. Moreover, curcumin, which is also 
an anti-oxidant and anti-inflammatory agent increased 
ROS and resulted in a depletion of glutathione during 
treatment with doxorubicin. This agent did not protect 
against apoptosis [81]. It seems that not all anti-oxidant 
agents have a protective effect during administration of 
doxorubicin s.  
Tadalafil is a potent long-acting selective inhibitor of 
cGMP-specific phosphodiesterase-5 and has known 
beneficial effects on acute myocardial infarction. cGMP 
takes part in regulating apoptosis. Simultaneous 
administration of tadalafil and doxorubicin in an in-vivo 
murine model resulted functional, biochemical, and 
histological improvement on the heart [82]. The same 
observation could be made with nicorandil, which is a 
stimulator of cGMP formation and decreases the 
calcium sensitivity of smooth muscle. It activates the 
sarcolemma pump to remove calcium and promotes K 
afflux. This indices hyperpolarization and hence 
vasodilation. Nicorandil inhibits oxidative stress-
induced myocyte apoptosis through the opening of 
mitochondrial K-ATP channels which can preserve 
mitochondrial energy production. The production of 
ROS has also been reduced and the ultrastructural 
changes have been mitigated. The ATP/ADP ratio has 
been preserved. The anti-tumor activity of doxorubicin 
remained unaltered [35]. Calcium antagonists such as 
amlodipine and felodipine also have beneficial effects. 
The latter has anti-oxidant properties which mitigates 
ultrastructural changes and cardiac damage [44]. 
Verapamil, another calcium antagonist, however, 
increases the susceptibility by inhibiting the multidrug 
resistance protein I MDR1 [17]. Other agents such as 
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angiotensin-converting enzyme inhibitors, angiotensin 
receptor blockers, beta-blockers, iron chelators, statins, 
and metformin are also subjected to research efforts  
[1, 9, 13].  
These tests were mostly performed in short-term 
animal models or in in-vitro H9c2 rat cardiomyocytes. 
Although this cell line has been validated, their results 
and those of in vivo animal models are not always 
reproducible with humans. This might be due to the fact 
that this toxicity not only acts through ROS [59] but has 
a chronic course. In general, all anti-oxidant treatments 
need further research since no effect has been 
observed with certainty. This is also true for anti-
inflammatory and anti-apoptotic substances [16]. Micro-
RNA have a major role as modulators of gene 
expression. These small molecules have a great 
potential as biomarkers in this area. Overexpression of 
miRNA-30 protects cardiomyocytes from doxorubicin-
related damage [83].  
Recently, polymer nanoparticles were developed for 
specific deliverance of chemotherapeutic agents to 
cancer cells. These particles of 400-500 nm are 
vehicles used for delivery of hydrophobic anti-cancer 
drugs, like doxorubicin. Such nanoparticles can be 
derived from poly-lactic-co-glycolic acid (or any 
biodegradable polymer such as chitosan, lipids, PEG 
etc. …) and quercetin (as a second, chemo-preventing 
agent). Modification can be obtained by coating with 
bovine serum albumin or histones to which 
chemotherapeutic agents such as doxorubicin are 
bound by sonication. After incubation, centrifugation 
and precipitation, these particles can be stored as 
freeze-dried or after lyophilizing. The nature of the 
surface of these nanoparticles is crucial to prevent 
clearance of these particles by the mononuclear 
phagocytic system. By a positive electric charge, these 
particles are attracted by negatively charged cancer 
cells. This results in a specific uptake and accumulation 
of these agents by the target cells. The technology has 
the advantage of formulating tailor-made drugs to suit 
the purpose of anti-cancer agents. Such nanoparticle 
formulation are expected to overcome multi-drug 
resistance by reaching and treatingthe target 
cancerous cells through their of size, charge and 
retention [84]. 
CONCLUSIONS 
The unravelling of the effects of doxorubicin s on 
the heart is very complex and far from complete. Even 
the study of gender effects did not show unequivocal 
results. Most affected pathways show mutual 
interaction, hence there changes are difficult to 
interpret. Most in-vivo experiments were acute or short 
term. Their results do not necessarily predict events in 
human cardiomyocytes and are not necessarily 
relevant for long-term outcomes in cancer patients. 
These long-term events can only be examined by 
cardiac biopsies, which are hard to come by. Genetic 
variations in susceptibility need to be taken into 
account. Examples are the presence or absence of 
HER-2 mediated receptors and single-nucleotide 
polymorphisms for NADPH oxidase and efflux 
transporters. Other cells than cardiomyocytes as well 
as the extracellular matrix have hardly been 
investigated. Nevertheless, changes induced by 
doxorubicin s can have a major effect on cardiac 
function, since there is a close structural relationship 
between all components of the heart which affects 
cardiac function. Long-term animal studies are 
warranted. There are some important limitations: the 
effects of combined chemotherapeutic regimens and of 
prior heart disease were not included. Follow-up 
protocols of patients with doxorubicin -induced 
cardiotoxicity was also considered outside the scope of 
this manuscript.  
ABBREVIATIONS 
ADP: adenosine diphosphate 
AMP: adenosine monophosphate  
AMPK: AMP-activated protein kinase  
ATP: adenosine triphosphate 
Bc-L: b-cell lymphoma  
BCRA Gene: breast cancer gene 
BNP: B-type natriuretic peptide  
CHF: congestive heart failure  
CMP: cardiomyopathy  
DNA: deoxyribonucleic acid  
ECM: extracellular matrix  
GSH: glutathione  
JNK: c-Jun N-terminal kinase  
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LV: left ventricle / LVEF: left ventricular ejection fraction  
MAPK: Mitogen-activated protein kinase 
MDR1: multi drug resistance protein-1 
MMP: matrix metalloproteinase 
mTOR: mammalian target of rapamycin  
NADPH: Nicotinamide adenine dinucleotide phosphate 
ROS: reactive oxygen species  
PI3: phosphatidyl-inositol-3-kinase 
PKB: proteinkinase B  
PPAR: peroxisomeproliferator-activate receptor 
TCL1A: T-cell lymphoma 1A 
TGF: transforming growth factor 
TIMP: tissue inhibitor of MMP  
UPP: ubiquitin proteasome pathway 
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